Daihan Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	216,554	208,614	204,195	195,911	184,268	171,463
Other Revenue	-0	-0	-	-	-	-0
Revenue	216,554	208,614	204,195	195,911	184,268	171,463
Revenue Growth	4.28%	2.16%	4.23%	6.32%	7.47%	3.24%
Cost of Revenue	152,832	144,169	134,788	130,599	124,455	115,781
Gross Profit	63,722	64,445	69,407	65,312	59,812	55,682
Selling, General & Admin	30,734	30,014	28,428	26,945	25,445	24,923
Research & Development	1,743	2,206	1,802	1,641	567.87	790.59
Amortization of Goodwill & Intangibles	-	-	-	-	-	0.5
Other Operating Expenses	575.46	449.95	479.63	411.75	387.26	334.4
Operating Expenses	33,575	33,259	31,327	29,517	26,844	26,614
Operating Income	30,147	31,186	38,081	35,795	32,968	29,068
Interest Expense	-2.42	-2.69	-1.81	-52.47	-593.43	-469.27
Interest & Investment Income	2,056	1,867	1,475	87.18	486.66	506.7
Currency Exchange Gain (Loss)	968.66	-239	1,229	504.71	525.35	687.03
Other Non Operating Income (Expenses)	-113.17	37.28	1,184	87.57	73.92	599.56
EBT Excluding Unusual Items	33,055	32,848	41,967	36,422	33,461	30,392
Gain (Loss) on Sale of Investments	-137.44	274.01	303.6	288.69	-	-
Gain (Loss) on Sale of Assets	18.36	31.38	58.03	22.53	-9.4	41.28
Pretax Income	32,936	33,153	42,329	36,734	33,451	30,433
Income Tax Expense	5,408	5,510	8,569	8,307	8,491	7,763
Net Income	27,528	27,644	33,759	28,426	24,961	22,670
Net Income to Common	27,528	27,644	33,759	28,426	24,961	22,670
Net Income Growth	-12.12%	-18.11%	18.76%	13.88%	10.10%	30.43%
Shares Outstanding (Basic)	-	6	6	6	6	6
Shares Outstanding (Diluted)	-	6	6	6	6	6
Shares Change	-	-	-	-1.75%	-0.25%	-
EPS (Basic)	-	4701.33	5741.34	4834.41	4170.67	3778.40
EPS (Diluted)	-	4701.33	5741.34	4834.41	4170.67	3778.40
EPS Growth	-	-18.11%	18.76%	15.92%	10.38%	30.43%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	20,165	481.53	19,841	17,580	20,378	28,767
Free Cash Flow Per Share	-	81.89	3374.38	2989.79	3405.01	4794.57
Gross Margin	29.43%	30.89%	33.99%	33.34%	32.46%	32.48%
Operating Margin	13.92%	14.95%	18.65%	18.27%	17.89%	16.95%
Profit Margin	12.71%	13.25%	16.53%	14.51%	13.55%	13.22%
Free Cash Flow Margin	9.31%	0.23%	9.72%	8.97%	11.06%	16.78%
EBITDA	41,780	40,406	45,362	44,459	42,176	40,479
EBITDA Margin	19.29%	19.37%	22.21%	22.69%	22.89%	23.61%
D&A For EBITDA	11,633	9,221	7,282	8,663	9,208	11,411
EBIT	30,147	31,186	38,081	35,795	32,968	29,068
EBIT Margin	13.92%	14.95%	18.65%	18.27%	17.89%	16.95%
Effective Tax Rate	16.42%	16.62%	20.24%	22.61%	25.38%	25.51%
Advertising Expenses	-	174.21	99.76	78.69	93.67	63.18